Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

NCT04241068 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04241068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04241068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
March 2, 2020
Completion date
July 22, 2024
Enrollment
1,696 (actual)
Sites
297

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease